This report provides comprehensive information on the therapeutic development for Bullous Pemphigoid, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bullous Pemphigoid and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
- iCo Therapeutics Inc.
- Immungenetics AG
- True North Therapeutics Inc
Key Topics Covered:
- Bullous Pemphigoid Overview
- Therapeutics Development
- Pipeline Products for Bullous Pemphigoid - Overview
- Pipeline Products for Bullous Pemphigoid - Comparative Analysis
- Bullous Pemphigoid - Therapeutics under Development by Companies
- Bullous Pemphigoid - Therapeutics under Investigation by Universities/Institutes
- Bullous Pemphigoid - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Bullous Pemphigoid - Products under Development by Companies
- Bullous Pemphigoid - Products under Investigation by Universities/Institutes
- Bullous Pemphigoid - Companies Involved in Therapeutics Development
For more information about this report visit http://www.researchandmarkets.com/research/vfrfz4/bullous